X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2026-07-15 | MPLT | Maplight Therapeutics, Inc. | Kroeger Christopher A. | CEO | S - Sale | $36.87 | -147,639 | 1,347,645 | -10% | -$5,443,722 | |||||
| M | 2026-07-15 | MPLT | Maplight Therapeutics, Inc. | Lillie James Woodruff | Chief Scientific Officer | S - Sale | $36.88 | -18,267 | 224,462 | -8% | -$673,636 | |||||
2026-07-16 | LYEL | Lyell Immunopharma, Inc. | Innovative Cellular Therapeutics Holdings Ltd | 10% | S - Sale | $13.73 | -10 | 2,857,490 | 0% | -$137 | ||||||
| M | 2026-07-15 | MPLT | Maplight Therapeutics, Inc. | Hanson Kristopher | GC | S - Sale | $36.82 | -16,508 | 145,823 | -10% | -$607,870 | |||||
| D | 2026-07-17 | MNKD | Mannkind Corp | Thomson David | EVP Genl Counsel, Secretary | S - Sale+OE | $4.05 | -24,109 | 797,554 | -3% | -$97,641 | |||||
| M | 2026-07-15 | MPLT | Maplight Therapeutics, Inc. | Foff Erin Pennock | Chief Medical Officer | S - Sale | $36.78 | -47,158 | 298,901 | -14% | -$1,734,490 | |||||
| D | 2026-07-17 | MNKD | Mannkind Corp | Binder Steven B. | Dir | S - Sale+OE | $4.06 | -52,485 | 824,918 | -6% | -$213,089 | |||||
2026-07-15 | INM | Inmed Pharmaceuticals Inc. | Adar1 Capital Management, LLC | 10% | P - Purchase | $1.56 | +1,000 | 801,000 | 0% | +$1,555 | ||||||
| A | 2026-07-14 | ETON | Eton Pharmaceuticals, Inc. | Opaleye Management Inc. | 10% | S - Sale | $37.54 | -28,315 | 2,705,000 | -1% | -$1,063,033 | |||||
| D | 2026-07-15 | SEPN | Septerna, Inc. | Bhatt Elizabeth | Pres, COO | S - Sale+OE | $33.99 | -4,000 | 174,209 | -2% | -$135,974 | |||||
2026-07-15 | CORT | Corcept Therapeutics Inc | Wilson James N | Dir | S - Sale | $88.30 | -10,000 | 1,484,543 | -1% | -$882,986 | ||||||
| D | 2026-07-15 | CORT | Corcept Therapeutics Inc | Mokari Atabak | CFO | S - Sale+OE | $87.71 | -40,000 | 16,130 | -71% | -$3,508,277 | |||||
| D | 2026-07-17 | ONC | Beone Medicines Ltd. | Oyler John | CEO | S - Sale+OE | $312.00 | -64,628 | 51,477,911 | 0% | -$20,163,907 | |||||
| DM | 2026-07-15 | ONC | Beone Medicines Ltd. | Oyler John | CEO | S - Sale+OE | $315.56 | -283,154 | 51,477,911 | -1% | -$89,351,598 | |||||
2026-07-16 | SDGR | Schrodinger, Inc. | Jain Rachit | EVP, CFO | S - Sale | $15.60 | -875 | 50,877 | -2% | -$13,647 | ||||||
| D | 2026-07-16 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $530.92 | -9,500 | 668,562 | -1% | -$5,043,689 | |||||
2026-07-15 | KROS | Keros Therapeutics, Inc. | Bienaime Jean Jacques | Dir | P - Purchase | $10.61 | +1,000 | 18,592 | +6% | +$10,610 | ||||||
| D | 2026-07-15 | ARDX | Ardelyx, Inc. | Raab Michael | Pres, CEO | S - Sale+OE | $5.06 | -41,668 | 1,703,730 | -2% | -$210,923 | |||||
| D | 2026-07-15 | PVLA | Palvella Therapeutics, Inc. | Goin Kathleen | COO | S - Sale+OE | $149.28 | -4,302 | 0 | -100% | -$642,191 | |||||
| D | 2026-07-15 | ARQT | Arcutis Biotherapeutics, Inc. | Welgus Howard G. | Dir | S - Sale+OE | $26.91 | -4,730 | 37,109 | -11% | -$127,284 | |||||
| M | 2026-07-15 | AQST | Aquestive Therapeutics, Inc. | Barber Daniel | Pres, CEO | S - Sale | $4.01 | -25,000 | 610,574 | -4% | -$100,192 | |||||
| M | 2026-07-14 | INM | Inmed Pharmaceuticals Inc. | Vivo Opportunity, LLC | 10% | P - Purchase | $1.55 | +20,546 | 818,076 | +3% | +$31,846 | |||||
| M | 2026-07-14 | BOLD | Boundless Bio, Inc. | Tang Kevin | 10% | P - Purchase | $2.43 | +63,969 | 2,854,072 | +2% | +$155,646 | |||||
| D | 2026-07-14 | GALT | Galectin Therapeutics Inc | Jamil Khurram | Chief Medical Officer | S - Sale+OE | $5.13 | -16,250 | 0 | -100% | -$83,285 | |||||
2026-07-14 | PTCT | Ptc Therapeutics, Inc. | Gravier Pierre | CFO | S - Sale | $80.35 | -3,494 | 83,986 | -4% | -$280,743 | ||||||
2026-07-14 | ETON | Eton Pharmaceuticals, Inc. | Opaleye Management Inc. | 10% | S - Sale | $37.54 | -28,315 | 2,705,000 | -1% | -$1,063,033 | ||||||
| M | 2026-07-14 | ADIL | Adial Pharmaceuticals, Inc. | Coastlands Capital LP | 10% | P - Purchase | $2.69 | +3,233 | 388,308 | +1% | +$8,691 | |||||
| D | 2026-07-15 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $530.35 | -9,500 | 668,728 | -1% | -$5,038,340 | |||||
| D | 2026-07-16 | UTHR | United Therapeutics Corp | Mahon Paul A | EVP, GC | S - Sale+OE | $533.69 | -8,300 | 45,172 | -16% | -$4,429,638 | |||||
2026-07-15 | ANIX | Anixa Biosciences Inc | Titterton Lewis H Jr | Dir | P - Purchase | $3.28 | +2,797 | 974,967 | 0% | +$9,174 | ||||||
2026-07-13 | MLYS | Mineralys Therapeutics, Inc. | Congleton Jon | CEO | S - Sale | $27.24 | -10,700 | 603,621 | -2% | -$291,441 | ||||||
| DM | 2026-07-13 | MLYS | Mineralys Therapeutics, Inc. | Rodman David Malcom | Chief Medical Officer | S - Sale+OE | $27.28 | -20,407 | 51,384 | -28% | -$556,671 | |||||
| M | 2026-07-13 | FULC | Fulcrum Therapeutics, Inc. | Tang Kevin | 10% | P - Purchase | $3.57 | +249,946 | 6,913,329 | +4% | +$891,067 | |||||
| D | 2026-07-15 | ORKA | Oruka Therapeutics, Inc. | Goncalves Joana | Chief Medical Officer | S - Sale+OE | $86.28 | -7,000 | 32,718 | -18% | -$603,938 | |||||
| D | 2026-07-14 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $526.83 | -9,500 | 668,728 | -1% | -$5,004,909 | |||||
2026-07-14 | RAPP | Rapport Therapeutics, Inc. | Ceesay Abraham | CEO | S - Sale | $40.00 | -8,210 | 642,275 | -1% | -$328,437 | ||||||
| M | 2026-07-13 | SLGL | Sol-Gel Technologies Ltd. | Opaleye Management Inc. | 10% | P - Purchase | $73.64 | +1,695 | 508,936 | 0% | +$124,819 | |||||
| M | 2026-07-13 | SHPH | Shuttle Pharmaceuticals Holdings, Inc. | Hrt Financial LP | 10% | S - Sale | $4.48 | -83,149 | 0 | -100% | -$372,704 | |||||
2026-07-13 | PHVS | Pharvaris N.V. | Modig Berndt | CEO | S - Sale | $34.97 | -2,292 | 1,082,917 | 0% | -$80,154 | ||||||
| D | 2026-07-14 | ONC | Beone Medicines Ltd. | Oyler John | CEO | S - Sale+OE | $305.95 | -145,861 | 51,477,911 | 0% | -$44,626,424 | |||||
| DM | 2026-07-10 | ONC | Beone Medicines Ltd. | Oyler John | CEO | S - Sale+OE | $303.18 | -60,218 | 51,637,304 | 0% | -$18,256,808 | |||||
| D | 2026-07-13 | LQDA | Liquidia Corp | Krepp Sarah | Chief Human Resource Officer | S - Sale+OE | $71.51 | -7,864 | 117,178 | -6% | -$562,361 | |||||
2026-07-13 | LQDA | Liquidia Corp | Khindri Sanjeev | Chief Development Officer | S - Sale | $71.51 | -1,185 | 65,947 | -2% | -$84,740 | ||||||
| D | 2026-07-13 | LQDA | Liquidia Corp | Kaseta Michael | CFO, COO | S - Sale+OE | $71.51 | -20,430 | 345,805 | -6% | -$1,460,965 | |||||
| D | 2026-07-13 | LQDA | Liquidia Corp | Jeffs Roger | CEO | S - Sale+OE | $71.51 | -35,249 | 2,218,688 | -2% | -$2,520,683 | |||||
| D | 2026-07-13 | LQDA | Liquidia Corp | Adair Jason | Chief Business Officer | S - Sale+OE | $71.51 | -7,863 | 217,126 | -3% | -$562,289 | |||||
| D | 2026-07-13 | LQDA | Liquidia Corp | Schundler Russell | GC | S - Sale+OE | $71.51 | -14,738 | 620,462 | -2% | -$1,053,926 | |||||
| D | 2026-07-13 | LQDA | Liquidia Corp | Saggar Rajeev | Chief Medical Officer | S - Sale+OE | $71.51 | -9,926 | 171,799 | -5% | -$709,816 | |||||
| D | 2026-07-13 | LQDA | Liquidia Corp | Moomaw Scott | Chief Commercial Officer | S - Sale+OE | $71.51 | -9,539 | 182,485 | -5% | -$682,142 | |||||
| D | 2026-07-13 | LQDA | Liquidia Corp | Boyle Dana | Chief Accounting Officer | S - Sale+OE | $71.51 | -9,002 | 169,519 | -5% | -$643,740 | |||||
| D | 2026-07-13 | IRON | Disc Medicine, Inc. | Quisel John D | CEO | S - Sale+OE | $74.96 | -33,000 | 226,064 | -13% | -$2,473,780 | |||||
| D | 2026-07-13 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $536.00 | -9,500 | 668,728 | -1% | -$5,091,949 | |||||
| D | 2026-07-10 | BCAX | Bicara Therapeutics Inc. | Mazumdar Claire | CEO | S - Sale+OE | $28.42 | -10,000 | 362,152 | -3% | -$284,198 | |||||
2026-07-13 | ANIP | Ani Pharmaceuticals Inc | Cook Meredith | SVP, GC, SEC. | S - Sale | $81.84 | -500 | 77,390 | -1% | -$40,920 | ||||||
| D | 2026-07-13 | CYTK | Cytokinetics Inc | Blum Robert I | Pres, CEO | S - Sale+OE | $82.02 | -7,500 | 381,986 | -2% | -$615,150 | |||||
| M | 2026-07-09 | BOLD | Boundless Bio, Inc. | Tang Kevin | 10% | P - Purchase | $2.42 | +91,585 | 2,790,103 | +3% | +$222,070 | |||||
| M | 2026-07-09 | RCUS | Arcus Biosciences, Inc. | Jaen Juan C. | Pres | S - Sale | $29.63 | -68,569 | 1,200,531 | -5% | -$2,031,919 | |||||
| D | 2026-07-09 | PTCT | Ptc Therapeutics, Inc. | Smith Mary L. | Dir | S - Sale+OE | $90.00 | -15,834 | 21,813 | -42% | -$1,425,060 | |||||
| D | 2026-07-09 | PTCT | Ptc Therapeutics, Inc. | Almstead Neil Gregory | CHIEF TECHNICAL OPS OFFICER | S - Sale+OE | $90.25 | -2,464 | 63,198 | -4% | -$222,376 | |||||
| D | 2026-07-13 | ORKA | Oruka Therapeutics, Inc. | Agarwal Arjun | SVP, Finance | S - Sale+OE | $84.63 | -9,999 | 15,312 | -40% | -$846,180 | |||||
| D | 2026-07-09 | DNTH | Dianthus Therapeutics, Inc. /De/ | Savitz Ryan | EVP, CFO, CBO | S - Sale+OE | $101.03 | -31,249 | 0 | -100% | -$3,157,151 | |||||
| D | 2026-07-09 | BBIO | Bridgebio Pharma, Inc. | Ellis Andrea | Dir | S - Sale+OE | $84.00 | -17,167 | 22,579 | -43% | -$1,442,028 | |||||
| D | 2026-07-09 | BBIO | Bridgebio Pharma, Inc. | Cook Jennifer E. | Dir | S - Sale+OE | $88.54 | -148,589 | 8,383 | -95% | -$13,156,008 | |||||
| D | 2026-07-10 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $544.60 | -9,500 | 668,728 | -1% | -$5,173,660 | |||||
2026-07-10 | INDV | Indivior Pharmaceuticals, Inc. | Heidbreder Christian | Chief Scientific Officer | S - Sale | $41.14 | -18,586 | 209,337 | -8% | -$764,628 | ||||||
| M | 2026-07-09 | MLTX | Moonlake Immunotherapeutics | Santos Da Silva Jorge | CEO | S - Sale | $20.02 | -102,225 | 2,774,893 | -4% | -$2,046,205 | |||||
| D | 2026-07-10 | RDHL | Redhill Biopharma Ltd. | Raday Gilead | COO | S - Sale+OE | $0.00 | -14,130,000 | 218,780,000 | -6% | -$1,413 | |||||
| M | 2026-07-09 | AMLX | Amylyx Pharmaceuticals, Inc. | Mazzariello Gina | GC | S - Sale | $17.96 | -30,000 | 179,090 | -14% | -$538,868 | |||||
| M | 2026-07-09 | SHPH | Shuttle Pharmaceuticals Holdings, Inc. | Hrt Financial LP | 10% | P - Purchase | $3.36 | +8,997 | 61,271 | +17% | +$30,212 | |||||
| M | 2026-07-09 | ADIL | Adial Pharmaceuticals, Inc. | Coastlands Capital LP | 10% | P - Purchase | $2.78 | +11,753 | 385,075 | +3% | +$32,638 | |||||
2026-07-10 | ANIX | Anixa Biosciences Inc | Kumar Amit | CEO | P - Purchase | $3.04 | +5,000 | 635,812 | +1% | +$15,200 | ||||||
2026-07-09 | PRQR | Proqr Therapeutics N.V. | De Boer Daniel Anton | CEO | P - Purchase | $1.74 | +150,000 | 300,000 | +100% | +$261,000 | ||||||
2026-07-08 | EVMN | Evommune, Inc. | Carver Kyle | CFO | P - Purchase | $13.26 | +1,000 | 60,335 | +2% | +$13,260 | ||||||
| D | 2026-07-09 | MLYS | Mineralys Therapeutics, Inc. | Rodman David Malcom | Chief Medical Officer | S - Sale+OE | $30.30 | -2,171 | 57,733 | -4% | -$65,781 | |||||
2026-07-08 | ANTX | An2 Therapeutics, Inc. | Eizen Joshua M | See Remarks | S - Sale | $4.17 | -5,945 | 206,554 | -3% | -$24,803 | ||||||
| DM | 2026-07-08 | CTNM | Contineum Therapeutics, Inc. | Lorrain Daniel S. | Chief Scientific Officer | S - Sale+OE | $16.00 | -1,040 | 145,312 | -1% | -$16,640 | |||||
| D | 2026-07-08 | ONC | Beone Medicines Ltd. | Lee Chan Henry | SVP, GC | S - Sale+OE | $302.46 | -664 | 338,884 | 0% | -$200,833 | |||||
| M | 2026-07-08 | SLGL | Sol-Gel Technologies Ltd. | Opaleye Management Inc. | 10% | P - Purchase | $73.80 | +529 | 507,241 | 0% | +$39,042 | |||||
2026-07-09 | NUVL | Nuvalent, Inc. | Pelish Henry E. | Chief Scientific Officer | S - Sale | $123.81 | -2,111 | 63,493 | -3% | -$261,363 | ||||||
| DM | 2026-07-08 | BCAX | Bicara Therapeutics Inc. | Cohlhepp Ryan | Pres, COO | S - Sale+OE | $28.98 | -28,750 | 181,641 | -14% | -$833,129 | |||||
| D | 2026-07-08 | BCAX | Bicara Therapeutics Inc. | Hyep Ivan | CFO | S - Sale+OE | $28.85 | -28,000 | 129,855 | -18% | -$807,672 | |||||
| D | 2026-07-09 | INSM | Insmed Inc | Lewis William | Chair, CEO | S - Sale+OE | $117.40 | -10,699 | 492,982 | -2% | -$1,256,084 | |||||
| D | 2026-07-10 | UTHR | United Therapeutics Corp | Malcolm Jan | Dir | S - Sale+OE | $550.59 | -325 | 450 | -42% | -$178,942 | |||||
2026-07-09 | URGN | Urogen Pharma Ltd. | Schoenberg Mark | Chief Medical Officer | S - Sale | $40.00 | -10,000 | 119,763 | -8% | -$400,000 | ||||||
| D | 2026-07-08 | AKTS | Aktis Oncology, Inc. | Ron-Bigger Shulamit | COO | S - Sale+OE | $27.75 | -50,000 | 0 | -100% | -$1,387,558 | |||||
| D | 2026-07-08 | AKTS | Aktis Oncology, Inc. | Czibere Akos | Chief Medical Officer | S - Sale+OE | $27.77 | -50,000 | 0 | -100% | -$1,388,701 | |||||
| D | 2026-07-09 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $551.13 | -9,500 | 668,728 | -1% | -$5,235,756 | |||||
| D | 2026-07-07 | IRON | Disc Medicine, Inc. | Yu Jonathan Yen-Wen | COO | S - Sale+OE | $82.50 | -100 | 54,324 | 0% | -$8,250 | |||||
| D | 2026-07-07 | IONS | Ionis Pharmaceuticals Inc | Bennett C Frank | EVP, Chief Scientific Officer | S - Sale+OE | $84.95 | -20,536 | 75,018 | -21% | -$1,744,623 | |||||
2026-07-09 | ABEO | Abeona Therapeutics Inc. | Vazzano Joseph Walter | CFO | S - Sale | $6.96 | -24,880 | 493,557 | -5% | -$173,257 | ||||||
2026-07-09 | ABEO | Abeona Therapeutics Inc. | Seshadri Vishwas | CEO | S - Sale | $6.96 | -67,971 | 1,306,108 | -5% | -$473,330 | ||||||
2026-07-09 | ABEO | Abeona Therapeutics Inc. | O'Malley Brendan M. | SVP, GC | S - Sale | $6.96 | -12,050 | 427,953 | -3% | -$83,913 | ||||||
2026-07-09 | ABEO | Abeona Therapeutics Inc. | Vasanthavada Madhav | Chief Commercial Officer | S - Sale | $6.96 | -12,606 | 290,623 | -4% | -$87,784 | ||||||
| D | 2026-07-07 | IONS | Ionis Pharmaceuticals Inc | Diaz Allene M. | Dir | S - Sale+OE | $85.42 | -10,111 | 3,811 | -73% | -$863,637 | |||||
2026-07-07 | IONS | Ionis Pharmaceuticals Inc | Kordasiewicz Holly B. | EVP, Chief Development Officer | S - Sale | $84.30 | -362 | 22,096 | -2% | -$30,517 | ||||||
| M | 2026-07-07 | SHPH | Shuttle Pharmaceuticals Holdings, Inc. | Hrt Financial LP | 10% | S - Sale | $3.45 | -29,111 | 52,274 | -36% | -$100,461 | |||||
| D | 2026-07-07 | IMNM | Immunome Inc. | Horn Kinney | CHIEF BUSINESS OFFICER | S - Sale+OE | $25.00 | -1,092 | 0 | -100% | -$27,300 | |||||
| D | 2026-07-07 | ATAI | Ataibeckley Inc. | Hershberg Robert | Dir | S - Sale+OE | $4.96 | -100,000 | 100,000 | -50% | -$496,000 | |||||
| D | 2026-07-07 | IDYA | Ideaya Biosciences, Inc. | Ruiz Briseno Andres | Chief Accounting Officer | S - Sale+OE | $40.01 | -9,550 | 26,466 | -27% | -$382,131 | |||||
| D | 2026-07-08 | SNDX | Syndax Pharmaceuticals Inc | Metzger Michael A | CEO | S - Sale+OE | $24.24 | -32,375 | 484,843 | -6% | -$784,776 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |